Intra-cellular therapies announces proposed public offering of common stock

New york, jan. 03, 2022 (globe newswire) -- intra-cellular therapies, inc. (nasdaq: itci), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (cns) disorders, today announced that it has commenced an underwritten public offering of $400 million of shares of its common stock. in connection with the offering, intra-cellular therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. all of the shares in the offering will be sold by intra-cellular therapies.
ITCI Ratings Summary
ITCI Quant Ranking